64007957MMY3006 (MajesTEC-9)09/12/2023 - 09/11/2026 (PI)
Janssen Research and Development, LLC
64407564MMY300205/05/2023 - 05/04/2026 (PI)
Janssen Research and Development, LLC
TAK-573-1501: A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma11/30/2022 - 11/29/2025 (PI)
Takeda Pharmaceuticals
Molecular characterization and therapeutic targeting of Protein Kinase D 2 in t(4;14) Multiple Myeloma05/01/2021 - 12/01/2024 (PI)
International Myeloma Society